Deal Snapshot: The companies first partnered in January 2019, with a focus on more than 20 diseases. The renewed deal will support development of additional disease models using artificial intelligence and machine learning.

Accenture released its Life Sciences Technology Vision 2022 report, including a survey of biopharma execs on trends like synthetic data and quantum computing.

Deal Snapshot: Following its January AI discovery alliance with Exscientia, Sanofi will employ Atomwise’s platform technology against five undisclosed drug targets.

Many industry leaders expect broad progress in the field of RNA technologies following the rapid and successful roll-out of mRNA vaccines against COVID-19 last year. Genetic medicines of various types, emerging platforms for tackling previously “undruggable” targets and the microbiome were among other areas singled out as areas to watch in 2022.